Unlock a More Complete View of Cancer
Guardant Infinity™ is a robust nondestructive DNA methylation technology ushering in a new era for precision oncology.1
One Technology—Powering Multiple Precision Oncology Applications
Our cutting-edge, proprietary platform delivers multiomic insights with genomic, epigenomic, and RNA-based fusion data that are scalable from research to the clinic.2
Guardant Infinity utilizes methylation technology that offers up to a 1300% increase in molecule recovery compared with bisulfite methods, providing broader coverage of the epigenome and increased sensitivity of circulating tumor DNA (ctDNA) detection for multiple applications.3
Discover MoreThe first and only platform that combines genomic, epigenomic, and RNA-based profiling to deliver multiomic insights
Novel, non-destructive methylation technology enabling far greater coverage and capture of tumor signal across the methylome
A single platform that powers our entire portfolio — building an expansive epigenomic real-world database
Guardant Infinity Can Both Quantify and Characterize Cancer
Quantify Cancer
Minimal residual disease (MRD) detection and molecular response monitoring
Learn MoreQuantify Cancer
Minimal residual disease (MRD) detection and molecular response monitoring
Minimal Residual Disease (MRD)
Detect residual disease after curative-intent treatment
Molecular Response
Early on-treatment changes from baseline to predict response to therapy
Response Monitoring
Monitor long-term response to therapy and predict progression
Characterize Cancer
Liquid and tissue molecular profiling
Liquid Comprehensive Molecular Profiling
Capture genomic and epigenomic biomarkers for multidimensional insights from liquid biopsy
Tissue Comprehensive Molecular Profiling
Capture genomic, epigenomic and RNA-based fusion insights from tissue biopsies